Randomized trial demonstrates AI-driven CT-derived fractional flow reserve's efficacy in coronary artery disease, suggesting improved diagnostics.
Noninvasive coronary CT angiography (CCTA) has been firmly established as a first-line imaging modality for evaluating suspected coronary artery disease (CAD) [1,2].Nevertheless, the well-known discordance between the severity of anatomical stenosis and functional ischemia remains a central challenge, particularly for intermediate lesions [3].CT-derived fractional flow reserve (CT-FFR) extends cardiac CT from morphology to physiology and has consistently demonstrated improved diagnostic accuracy compared with CCTA alone [4][5][6].Computational fluid dynamics-based off-site CT-FFR (e.g., HeartFlow) has been the most extensively validated, and artificial intelligence (AI)-based on-site CT-FFR aims to enhance workflow integration and scalability [7].AI-based CT-FFR is widely anticipated as a scalable and workflow-integrated solution that offers rapid on-site analysis without additional scanning [5,8].In randomized
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: